硼中子俘获治疗是癌症治疗的一种有前途的方法，但有效硼剂的输送具有挑战性。为了满足高效硼剂输送的要求，我们使用了一个混合纳米颗粒，包括一个载有普鲁兰纳米凝胶的碳硼烷和疏水化的硼氧化物纳米颗粒（HBNGs），可制备高浓度的硼剂以实现高效输送。HBNGs在体外表现出对结肠癌26细胞的更好的抗癌效果，比临床硼剂L-BPA/果糖复合物增强细胞内硼剂的积累和滞留量。HBNGs在肿瘤中的积累，由于强化的渗透和滞留效应，使得硼剂高度选择性地输送到肿瘤，满足临床需求。使用HBNGs进行静脉注射的硼中子俘获治疗（BNCT）减少了肿瘤体积，而没有引起显著的体重损失，并且在完全消退后三个月内没有观察到肿瘤再生。HBNGs的治疗效果优于L-BPA/果糖复合物。BNCT与HBNGs是癌症治疗的有前途的方法。版权所有©2023 Elsevier Inc.

Boron neutron capture therapy shows is a promising approach to cancer therapy, but the delivery of effective boron agents is challenging. To address the requirements for efficient boron delivery, we used a hybrid nanoparticle comprising a carborane = bearing pullulan nanogel and hydrophobized boron oxide nanoparticle (HBNGs) enabling the preparation of highly concentrated boron agents for efficient delivery. The HBNGs showed better anti-cancer effects on Colon26 cells than a clinically boron agent, L-BPA/fructose complex, by enhancing the accumulation and retention amount of the boron agent within cells in vitro. The accumulation of HBNGs in tumors, due to the enhanced permeation and retention effect, enabled the delivery of boron agents with high tumor selectivity, meeting clinical demands. Intravenous injection of boron neutron capture therapy (BNCT) using HBNGs decreased tumor volume without significant body weight loss, and no regrowth of tumor was observed three months after complete regression. The therapeutic efficacy of HBNGs was better than that of L-BPA/fructose complex. BNCT with HBNGs is a promising approach to cancer therapeutics.Copyright © 2023 Elsevier Inc. All rights reserved.